Treatment Category Profile

Treatment Name:	Auto-Lymphocyte Therapy	Known as: Also Known As:	ALT
Treatment Type:	Immunotherapy	Status:	FDA Approved (phase II)
ALT, Autologous Lymphocyte Therapy, is an immunotherapy that has been under investigation since 1980, both in the setting of active metastasis and as an adjuvant therapy. Several adjuvant studies with small patient numbers have recorded increased survival times and/or time to recurrence.

   Articles related to this Treatment

1 Radiologic follow-up of patients with T1-3a,b,c or T4N+M0 renal cell carcinoma after radical nephrectomy. PubMed Dec 1, 1998 2 Randomized, controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in T1-3a,b,c or T4N+,M 0 renal cell carcinoma. ASCO Online Jan 1, 1997 3 Biotherapy of advanced cancer by infusion of in vitro activated Pubmed Nov 17, 1995 4 Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II). Pubmed Jul 1, 1995 5 Treatment of metastatic renal cell carcinoma with autolymphocyte therapy. Pubmed May 1, 1990 6 Effect of autolymphocyte therapy on survival and quality of life in patients Pubmed Apr 28, 1990